EHA 2022 Conference Coverage


 

Lecture Summary - EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Higher-Risk MDS: 5F9005 Phase 1b Study Results

June 22, 2022

0 Comments
Login to view comments. Click here to Login